Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of TLL-018 in moderate-to-severe active rheumatoid arthritis with inadequate response or intolerance to csDMARDs
CTR20262667Phase 2Active
- Sponsor
- Highlight Pharmaceutical
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of girocitinib in rheumatoid arthritis (RA), sponsored by Highlight Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
girocitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20262667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262667.